bronchopulmonary dysplasia
Chiesi and Oak Hill enrol first European patient in phase 2b premature birth study
The trial is evaluating OHB-607 for preventing bronchopulmonary dysplasia and other complications
Chiesi Group invests €400m to establish biotech centre of excellence in Italy
The facility is dedicated to developing and producing monoclonal antibodies, enzymes and other proteins
Chiesi targets patient adherence via mobile app
Initiative will see asthma and COPD patients receive device training support
Chiesi’s ultra-rare genetic disorder therapy wins European backing
Lamzede is set to become the first approved therapy for Alpha-Mannosidosis
